File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Hepatocellular carcinoma: screening and non-surgical treatment

TitleHepatocellular carcinoma: screening and non-surgical treatment
Authors
KeywordsHepatocellular carcinoma
Pathology
Screening
Treatment
Issue Date1999
PublisherBlackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/ASH
Citation
Annals of The College of Surgeons of Hong Kong, 1999, v. 3 n. 4, p. 107-111 How to Cite?
AbstractHepatocellular carcinoma (HCC) is the second commonest cancer in Hong Kong. Recent advances show that HCC can be derived from hepatocytes and from progenitor oval cells. Those from progenitor oval cells express both hepatocyte and biliary markers and are associated with poorer differentiation, more cellular proliferation, more aggressive clinical course and poorer prognosis. Patients with HCC usually present late and the choice of treatment modalities will be limited. Screening for early subclinical HCC in high-risk groups is indicated. In patients diagnosed by screening, the clinical parameters were significantly more favourable, with a higher resectability rate, a higher chance of responding to transarterial chemoembolization (TACE) and a better survival. Treatment for HCC at present is still not satisfactory because of the late presentation, low resection rate, the high recurrence/new occurrence rate and the high prevalence of background cirrhosis. Surgical resection remains the first choice of treatment. However, there is a high recurrence rate. Medical treatment for inoperable HCC can be divided into systemic and local/regional therapy. To date, there are relatively few randomized controlled trials. Systemic therapy consists of the use of doxorubicin, alpha-interferon, tamoxifen or combination therapy. For the local/regional therapy, alcohol injection and TACE with lipiodol are the two commonly used methods. Selective intra-arterial infusion of 90yttrium has also been described. Randomized controlled trials are urgently needed to assess the efficacy of various medical treatments.
Persistent Identifierhttp://hdl.handle.net/10722/78568
ISSN

 

DC FieldValueLanguage
dc.contributor.authorYuen, MFen_HK
dc.contributor.authorLai, CLen_HK
dc.date.accessioned2010-09-06T07:44:19Z-
dc.date.available2010-09-06T07:44:19Z-
dc.date.issued1999en_HK
dc.identifier.citationAnnals of The College of Surgeons of Hong Kong, 1999, v. 3 n. 4, p. 107-111en_HK
dc.identifier.issn1028-4001-
dc.identifier.urihttp://hdl.handle.net/10722/78568-
dc.description.abstractHepatocellular carcinoma (HCC) is the second commonest cancer in Hong Kong. Recent advances show that HCC can be derived from hepatocytes and from progenitor oval cells. Those from progenitor oval cells express both hepatocyte and biliary markers and are associated with poorer differentiation, more cellular proliferation, more aggressive clinical course and poorer prognosis. Patients with HCC usually present late and the choice of treatment modalities will be limited. Screening for early subclinical HCC in high-risk groups is indicated. In patients diagnosed by screening, the clinical parameters were significantly more favourable, with a higher resectability rate, a higher chance of responding to transarterial chemoembolization (TACE) and a better survival. Treatment for HCC at present is still not satisfactory because of the late presentation, low resection rate, the high recurrence/new occurrence rate and the high prevalence of background cirrhosis. Surgical resection remains the first choice of treatment. However, there is a high recurrence rate. Medical treatment for inoperable HCC can be divided into systemic and local/regional therapy. To date, there are relatively few randomized controlled trials. Systemic therapy consists of the use of doxorubicin, alpha-interferon, tamoxifen or combination therapy. For the local/regional therapy, alcohol injection and TACE with lipiodol are the two commonly used methods. Selective intra-arterial infusion of 90yttrium has also been described. Randomized controlled trials are urgently needed to assess the efficacy of various medical treatments.-
dc.languageengen_HK
dc.publisherBlackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/ASH-
dc.relation.ispartofAnnals of The College of Surgeons of Hong Kongen_HK
dc.rightsThe definitive version is available at www.blackwell-synergy.com-
dc.subjectHepatocellular carcinoma-
dc.subjectPathology-
dc.subjectScreening-
dc.subjectTreatment-
dc.titleHepatocellular carcinoma: screening and non-surgical treatmenten_HK
dc.typeArticleen_HK
dc.identifier.emailYuen, MF: mfyuen@hkucc.hku.hken_HK
dc.identifier.emailLai, CL: hrmelcl@hku.hk-
dc.identifier.authorityYuen, MF=rp00479en_HK
dc.identifier.doi10.1046/j.1442-2034.1999.00033.x-
dc.identifier.hkuros50610en_HK
dc.identifier.volume3-
dc.identifier.issue4-
dc.identifier.spage107-
dc.identifier.epage111-
dc.publisher.placeAustralia-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats